These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2019467)

  • 1. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast.
    Williams G; Anderson E; Howell A; Watson R; Coyne J; Roberts SA; Potten CS
    Int J Cancer; 1991 May; 48(2):206-10. PubMed ID: 2019467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast.
    Battersby S; Robertson BJ; Anderson TJ; King RJ; McPherson K
    Br J Cancer; 1992 Apr; 65(4):601-7. PubMed ID: 1562470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
    Greene KE; Kettel LM; Yen SS
    Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptive use influences resting breast proliferation.
    Anderson TJ; Battersby S; King RJ; McPherson K; Going JJ
    Hum Pathol; 1989 Dec; 20(12):1139-44. PubMed ID: 2591943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis.
    Jorgensen C; Picot MC; Bologna C; Sany J
    Ann Rheum Dis; 1996 Feb; 55(2):94-8. PubMed ID: 8712873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
    Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lynestrenol 1 mg.-mestranol 0.1 mg: a new low dose oral contraceptive: a clinical study.
    Kamal I; Hefnawi F; Younis N
    Egypt Popul Fam Plann Rev; 1970 Jun; 3(1):11-5. PubMed ID: 12254506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland.
    Russo J; Ao X; Grill C; Russo IH
    Breast Cancer Res Treat; 1999 Feb; 53(3):217-27. PubMed ID: 10369068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of combined oral contraceptives on breast epithelial proliferation in young women.
    Garcia y Narvaiza D; Navarrete MA; Falzoni R; Maier CM; Nazário AC
    Breast J; 2008; 14(5):450-5. PubMed ID: 18657146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell turnover in the "resting" human breast: influence of parity, contraceptive pill, age and laterality.
    Anderson TJ; Ferguson DJ; Raab GM
    Br J Cancer; 1982 Sep; 46(3):376-82. PubMed ID: 7126427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sex steroids on proliferation in normal mammary tissue.
    Söderqvist G
    Ann Med; 1998 Dec; 30(6):511-24. PubMed ID: 9920352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study.
    Cooper JA; Rohan TE; Cant EL; Horsfall DJ; Tilley WD
    Br J Cancer; 1989 Jan; 59(1):119-25. PubMed ID: 2757918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen and progesterone receptors in the normal female breast.
    Ricketts D; Turnbull L; Ryall G; Bakhshi R; Rawson NS; Gazet JC; Nolan C; Coombes RC
    Cancer Res; 1991 Apr; 51(7):1817-22. PubMed ID: 2004366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of progesterone receptor mRNA in the endometrium during the normal menstrual cycle and in Norplant users.
    Lau TM; Witjaksono J; Affandi B; Rogers PA
    Hum Reprod; 1996 Dec; 11(12):2629-34. PubMed ID: 9021364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles.
    Going JJ; Anderson TJ; Battersby S; MacIntyre CC
    Am J Pathol; 1988 Jan; 130(1):193-204. PubMed ID: 3337211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of oral contraceptive pills and the natural menstrual cYCLe on arterial stiffness and hemodynamICs (CYCLIC).
    Yu A; Giannone T; Scheffler P; Doonan RJ; Egiziano G; Gomez YH; Papaioannou TG; Daskalopoulou SS
    J Hypertens; 2014 Jan; 32(1):100-7. PubMed ID: 24326993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential study of plasma euglobulin fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen.
    Jespersen J
    Gynecol Obstet Invest; 1983; 15(5):266-74. PubMed ID: 6852646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of age and menstrual cycle upon proliferative activity of the normal human breast.
    Potten CS; Watson RJ; Williams GT; Tickle S; Roberts SA; Harris M; Howell A
    Br J Cancer; 1988 Aug; 58(2):163-70. PubMed ID: 3166907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral contraceptives as related to cancer and benign lesions of the breast.
    Fasal E; Paffenbarger RS
    J Natl Cancer Inst; 1975 Oct; 55(4):767-73. PubMed ID: 1185801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of age, sex and the oral contraceptive on the platelet membrane fibrinogen binding site (glycoprotein IIb/IIIa).
    Cahill M; Mistry R; Chapman C; Wood JK; Barnett DB
    Br J Clin Pharmacol; 1992 Jan; 33(1):11-5. PubMed ID: 1540480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.